CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Right now it’s used for severe treatment-resistant depression. But there’s an ongoing discussion that people with severe depression may do well using it earlier in treatment. I think you’ll ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The approval makes the treatment the first and only monotherapy for adults ... in which Spravato alone showed a rapid and ...